2023 World Conference on Lung Cancer (Posters)-EP06.03. Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital

EP06.03. Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital - PDF(Slides)

Back to course

Pdf Summary

A study conducted in Bangladesh aimed to compare the frequency of genomic alterations identified by two next-generation sequencing methods, Comprehensive Genomic Profiling (CGP) and Hotspot panel test, in advanced lung cancer patients in a tertiary hospital. The study found that CGP has a higher probability of detecting actionable genomic alterations compared to the Hotspot panel test. CGP can also identify novel genomic alterations that may have clinical significance. Although CGP is more expensive, it should be preferred if the patient can afford it. These findings have implications for patient management and personalized treatment approaches in Bangladesh. However, the study's sample size is limited, and larger studies are needed to confirm these findings and establish guidelines for genomic testing in advanced lung cancer patients in Bangladesh.<br /><br />The study collected data from the hospital information system, including 4435 oncology outpatient cases, with 760 cases being primary lung cancer, mostly in stage III-IV. CGP was conducted on 21 patients, while the Hotspot panel test was conducted on 41 patients. Tissue samples and liquid biopsies were used for testing when tissue samples were unavailable. CGP identified more actionable genomic alterations than the Hotspot panel test, including FGFR1, MLL2, MTAP, MYC, STK11, RB1, NF1, etc. The Hotspot panel test had a higher probability of identifying no genomic alterations compared to CGP. The study also presented a visual representation of the frequency of genomic alterations identified by CGP and the Hotspot panel test.<br /><br />In conclusion, this study suggests that CGP is more effective in detecting actionable genomic alterations in advanced lung cancer patients compared to the Hotspot panel test. However, larger studies are needed to validate these findings and establish guidelines for genomic testing in Bangladesh.

Asset Subtitle

Qamruzzaman Chowdhury

Meta Tag

Speaker Qamruzzaman Chowdhury

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Bangladesh

genomic alterations

next-generation sequencing

Comprehensive Genomic Profiling

Hotspot panel test

lung cancer

actionable genomic alterations

novel genomic alterations

patient management

personalized treatment